基于无种族方程估算的肾小球滤过率与黑种人与非黑种人肾衰竭及死亡风险的关联
该回顾性个体水平数据分析纳入美国5个一般人群和3个慢性肾脏病队列的62011名参与者,评估含或不含种族及胱抑素C的eGFR方程是否记录黑种人与非黑种人在肾衰竭和死亡风险上的差异。结果显示,不含种族但包含肌酐和胱抑素C的eGFR方程在整个eGFR范围内显示了肾衰竭和死亡风险的种族差异,而仅含肌酐的不含种族方程未显示此差异。
要点
- 在eGFR为60 mL/min/1.73 m2时,黑种人与非黑种人相比,肾衰竭的风险比在含种族的eGFRcr方程中为2.8,在eGFRcys方程中为3.0,在eGFRcr-cys方程中为2.8,而在不含种族的eGFRcr方程中为1.3。
- 黑种人与非黑种人相比,eGFR低于60 mL/min/1.73 m2的患病率比在不含种族的eGFRcr方程中为1.8,在eGFRcys方程中为0.95,在eGFRcr-cys方程中为1.2,在含种族的eGFRcr方程中为0.98。
- 作者认为,在评估与低eGFR相关的肾衰竭和死亡风险的种族差异时,eGFRcr-cys方程可能优于不含种族的eGFRcr方程。
核心结论
- 在美国8个包含黑种人和非黑种人的队列的回顾性分析中,不含种族但包含肌酐和胱抑素C的eGFR方程在整个eGFR范围内显示了肾衰竭和死亡风险的种族差异,而不含种族仅含肌酐的eGFR方程未显示此差异。
研究设计与样本
- 回顾性个体水平数据分析,纳入来自美国5个一般人群队列和3个慢性肾脏病队列的62011名参与者,具备血清肌酐、胱抑素C以及1988年至2018年肾衰竭和死亡的随访数据。
主要发现
- 在62011名参与者中(黑种人20773名,非黑种人41238名;平均年龄63岁;女性占53%),黑种人与非黑种人相比,eGFR低于60 mL/min/1.73 m2的患病率比(95%CI;患病率)在含种族的eGFRcr方程中为0.98(95%CI,0.93-1.03;11% vs 12%),在eGFRcys方程中为0.95(95%CI,0.91-0.98;17% vs 18%),在eGFRcr-cys方程中为1.2(95%CI,1.2-1.3;13% vs 11%),而在不含种族的eGFRcr方程中为1.8(95%CI,1.7-1.8;15% vs 9%)。
- 在平均13年随访期间,黑种人和非黑种人参与者中分别有8%和4%发生肾衰竭,分别有34%和39%死亡。
- 在eGFR为60 mL/min/1.73 m2时,黑种人与非黑种人相比,肾衰竭的风险比在含种族的eGFRcr方程中为2.8(95%CI,1.6-4.9),在eGFRcys方程中为3.0(95%CI,1.5-5.8),在eGFRcr-cys方程中为2.8(95%CI,1.4-5.4),而在不含种族的eGFRcr方程中为1.3(95%CI,0.8-2.1)。
- 黑种人与非黑种人相比,肾衰竭的5年绝对风险差在含种族的eGFRcr方程中为1.4%(95%CI,0.2%-2.6%),在eGFRcys方程中为1.1%(95%CI,0.2%-1.9%),在eGFRcr-cys方程中为1.3%(95%CI,0%-2.6%),而在不含种族的eGFRcr方程中为0.37%(95%CI,-0.32%至1.05%)。
- 死亡风险呈现相似的模式。
临床怎么用
- 作者认为,在评估与低eGFR相关的肾衰竭和死亡风险的种族差异时,eGFRcr-cys方程可能优于不含种族的eGFRcr方程。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: At a given estimated glomerular filtration rate (eGFR), individuals who are Black have higher rates of mortality and kidney failure with replacement therapy (KFRT) compared with those who are non-Black. Whether the recently adopted eGFR equations without race preserve racial differences in risk of mortality and KFRT at a given eGFR is unknown. OBJECTIVE: To assess whether eGFR equations with and without race and cystatin C document racial differences in risk of KFRT and mortality in populations including Black and non-Black participants. DESIGN, SETTING, AND PARTICIPANTS: Retrospective individual-level data analysis of 62 011 participants from 5 general population and 3 chronic kidney disease (CKD) US-based cohorts with serum creatinine, cystatin C, and follow-up for KFRT and mortality from 1988 to 2018. EXPOSURES: Chronic Kidney Disease Epidemiology Collaboration equation with serum creatinine (eGFRcr with and without race), cystatin C (eGFRcys without race), or both markers (eGFRcr-cys without race). MAIN OUTCOMES AND MEASURES: The prevalence of decreased eGFR at baseline and hazard ratios of KFRT and mortality in Black vs non-Black participants were calculated, adjusted for age and sex. Analyses were performed within each cohort and with random-effect meta-analyses of the models. RESULTS: Among 62 011 participants (20 773 Black and 41 238 non-Black; mean age, 63 years; 53% women), the prevalence ratio (95% CI; percent prevalences) of eGFR less than 60 mL/min/1.73 m2 comparing Black with non-Black participants was 0.98 (95% CI, 0.93-1.03; 11% vs 12%) for eGFRcr with race, 0.95 (95% CI, 0.91-0.98; 17% vs 18%) for eGFRcys, and 1.2 (95% CI, 1.2-1.3; 13% vs 11%) for eGFRcr-cys but was 1.8 (95% CI, 1.7-1.8; 15% vs 9%) for eGFRcr without race. During a mean follow-up of 13 years, 8% and 4% of Black and non-Black participants experienced KFRT and 34% and 39% died, respectively. Decreased eGFR was associated with significantly greater risk of both outcomes for all equations. At an eGFR of 60 mL/min/1.73 m2, the hazard ratios for KFRT comparing Black with non-Black participants were 2.8 (95% CI, 1.6-4.9) for eGFRcr with race, 3.0 (95% CI, 1.5-5.8) for eGFRcys, and 2.8 (95% CI, 1.4-5.4) for eGFRcr-cys vs 1.3 (95% CI, 0.8-2.1) for eGFRcr without race. The 5-year absolute risk differences for KFRT comparing Black with non-Black participants were 1.4% (95% CI, 0.2%-2.6%) for eGFRcr with race, 1.1% (95% CI, 0.2%-1.9%) for eGFRcys, and 1.3% (95% CI, 0%-2.6%) for eGFRcr-cys vs 0.37% (95% CI, -0.32% to 1.05%) for eGFRcr without race. Similar patterns were observed for mortality. CONCLUSIONS AND RELEVANCE: In this retrospective analysis of 8 US cohorts including Black and non-Black individuals, the eGFR equation without race that included creatinine and cystatin C, but not the eGFR equation without race that included creatinine without cystatin C, demonstrated racial differences in the risk of KFRT and mortality throughout the range of eGFR. The eGFRcr-cys equation may be preferable to the eGFRcr equation without race for assessing racial differences in the risk of KFRT and mortality associated with low eGFR.
引用
- Gutiérrez OM, Sang Y, Grams ME, et al. Association of Estimated GFR Calculated Using Race-Free Equations With Kidney Failure and Mortality by Black vs Non-Black Race. JAMA. 2022. PMID: 35667006. doi:10.1001/jama.2022.8801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。